Cellectis (CLLS) Beginning Cash Balance (2015 - 2026)
Cellectis (CLLS) posted quarterly Beginning Cash Balance of $61.5 million for Q1 2026, down 57.05% year-over-year from $143.3 million in Q1 2025, and down 57.05% quarter-over-quarter from $143.3 million in Q1 2025.
Cellectis (CLLS) Beginning Cash Balance (2015 - 2026) Analysis & Trends
Cellectis' Beginning Cash Balance history runs 12 years deep, the most recent figure standing at $61.5 million for Q1 2026.
- In Q1 2026, Beginning Cash Balance fell 57.05% year-over-year to $61.5 million; the TTM figure through Mar 2026 stood at $204.8 million (down 26.85% YoY), while the FY2016 annual figure was $347.9 million, up 178.76% from the prior year.
- Beginning Cash Balance for Q1 2026 stood at $61.5 million, down from $143.3 million in the prior quarter.
- The five-year high for Beginning Cash Balance was $185.6 million in Q1 2022, with the low at $61.5 million in Q1 2026.
- The 5-year median for Beginning Cash Balance is $136.7 million (2024), against an average of $124.1 million.
- The sharpest annual moves came in 2024 and 2026: Beginning Cash Balance jumped 46.66% in 2024, then tumbled 57.05% in 2026.
- Cellectis' Beginning Cash Balance stood at $185.6 million in 2022, then plunged by 49.79% to $93.2 million in 2023, then surged by 46.66% to $136.7 million in 2024, then rose by 4.79% to $143.3 million in 2025, then sank by 57.05% to $61.5 million in 2026.
- Business Quant data shows CLLS's Beginning Cash Balance at $61.5 million in Q1 2026, $143.3 million in Q1 2025, and $136.7 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61.53 Mn |
| Mar 31, 2026 | 61.53 Mn |
| Mar 31, 2025 | 143.25 Mn |
| Mar 31, 2025 | 143.25 Mn |
| Mar 31, 2024 | 136.71 Mn |
| Mar 31, 2024 | 136.71 Mn |
| Mar 31, 2023 | 93.22 Mn |
| Mar 31, 2023 | 93.22 Mn |
| Mar 31, 2022 | 185.64 Mn |
| Mar 31, 2022 | 185.64 Mn |
| Mar 31, 2021 | 241.15 Mn |
| Mar 31, 2021 | 241.15 Mn |
| Mar 31, 2020 | 340.52 Mn |
| Mar 31, 2020 | 340.52 Mn |
| Mar 31, 2019 | 451.50 Mn |
| Mar 31, 2019 | 451.50 Mn |
| Mar 31, 2018 | 256.38 Mn |
| Mar 31, 2018 | 256.38 Mn |
| Mar 31, 2017 | 254.57 Mn |
| Mar 31, 2017 | 254.57 Mn |